Condition: Generalized Pustular Psoriasis · Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).
This description comes directly from the study's public registry record.
Guodong Zhou · +86 13636638684 · guodong.zhou@huaota.com
Qiaoxia Qian, Master · +86 18555690860 · qiaoxia.qian@huaota.com
Always discuss trial participation with your own doctor first.
| Peking University People's Hospital (PKUPH) | Beijing, China | Recruiting |
| Peking University People's Hospital | Beijing, China | Recruiting |
| The Second affiliated Hospital zhejiang University School of Medicine | Hangzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06477536